By creating seminal tools for the computational analysis of massively parallel sequencing data, the Getz group has generated vital pipelines and the analysis framework for large-scale processing and systematic analysis of cancer genome datasets. Through collaborations with an international network of investigators, we have gathered whole-exome, matched transcriptome, and methylome data from >1000 CLL patients. Through saturation analysis and statistical modeling, we have calculated this collection of samples to provide sufficient statistical power to detect all intermediate and high frequency genetic drivers of this disease (94% power to detect events in >2% of patients), based on the background mutation frequency of CLLs. The goals of our analyses are to: (1) Build a comprehensive catalog of all genetic and epigenetic drivers of CLL and their interdependencies, both clonal and subclonal, integrating information on somatic point mutations, copy- number changes, and DNA methylation; (2) Integrate all genomic data modalities to identify molecular subtypes of CLL and associate with drivers, cellular processes and cancer hallmarks; and (3) Develop new models to predict outcome based on the genomic map of CLL subtypes. Designing a framework and tools to maximize our understanding of the relevant genetic and epigenetic determinants of CLL development and response to treatment is the focus of this project. These results and framework will generate a valuable resource for the CLL and the broader cancer community.

Public Health Relevance

Chronic lymphocytic leukemia (CLL) can take extreme clinical courses, ranging from very stable to a fast progressing and aggressive disease. Part of this variability can be explained by the diversity in the molecular make up of the cancer cells across CLL patients. In this proposal we will create the world's largest map of CLL with the goal of matching the clinical features of CLL with the full spectrum of its molecular characteristics. These detailed layers of molecular information will used to improve our ability to predict the course of CLL disease and response to treatment, including new targeted agents that are becoming increasingly available.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA206978-02
Application #
9342753
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Lampson, Benjamin L; Brown, Jennifer R (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol 11:185-194
Wang, Lili; Livak, Kenneth J; Wu, Catherine J (2018) High-dimension single-cell analysis applied to cancer. Mol Aspects Med 59:70-84
Landau, Dan A; Sun, Clare; Rosebrock, Daniel et al. (2017) The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun 8:2185
Compagno, Mara; Wang, Qi; Pighi, Chiara et al. (2017) Phosphatidylinositol 3-kinase ? blockade increases genomic instability in B cells. Nature 542:489-493
Ten Hacken, Elisa; Guièze, Romain; Wu, Catherine J (2017) SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell 32:716-716.e1
Murphy, E J; Neuberg, D S; Rassenti, L Z et al. (2017) Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia 31:1348-1354
Deng, J; Isik, E; Fernandes, S M et al. (2017) Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075-2084
Tiao, G; Improgo, M R; Kasar, S et al. (2017) Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia 31:2244-2247
Wang, Lili; Fan, Jean; Francis, Joshua M et al. (2017) Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res 27:1300-1311

Showing the most recent 10 out of 11 publications